NASDAQ:KTOV Purple Biotech (KTOV) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$3.81▼$4.9452-Week Range$2.20▼$14.40Volume104,331 shsAverage Volume1.18 million shsMarket Capitalization$6.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Purple Biotech alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Purple Biotech Stock (NASDAQ:KTOV)Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.Read More Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report KTOV Stock News HeadlinesMay 21, 2024 | markets.businessinsider.comBuy Rating Justified by Purple Biotech’s Promising Clinical Data and Market PotentialApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed on Purple Biotech’s CM24 Favorable Interim Phase 2 Results in PDAC TreatmentJuly 26, 2024 | DTI (Ad)Heard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…March 6, 2024 | markets.businessinsider.comPromising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical AdvancementsNovember 21, 2023 | benzinga.comPurple Biotech: Q3 Earnings InsightsNovember 21, 2023 | msn.comPurple Biotech GAAP EPS of -$0.23October 30, 2023 | msn.comPurple Biotech files to sell 4.65M ADS for holdersAugust 25, 2023 | benzinga.comAlukovinyl Provides Customised And Innovative Purple Car Wrap Films For Car Owners WorldwideJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.August 24, 2023 | benzinga.comPurple Biotech Stock (NASDAQ:PPBT), Earnings Estimates, EPS, and RevenueAugust 22, 2023 | benzinga.comPurple Biotech Reports Second Quarter 2023 Financial ResultsJuly 19, 2023 | seekingalpha.comPPBT Purple Biotech Ltd.July 9, 2023 | latimes.comPurple Carrot Discount CodesJune 29, 2023 | reuters.comPurple Promo Codes 2023May 17, 2023 | markets.businessinsider.comPurple Biotech (PPBT) Receives a Buy from H.C. WainwrightMarch 24, 2023 | seekingalpha.comPurple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEOSeptember 9, 2022 | finance.yahoo.comRapidly Growing Purple Brands Announces New Director of WinemakingAugust 12, 2022 | finance.yahoo.com‘Purple Hearts’ Star Sofia Carson and Director Elizabeth Allen Rosenbaum Defend Netflix Film After Backlash: ‘Our Intentions Are Very Pure’See More Headlines Receive KTOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KTOV CUSIPN/A CIK1614744 Webwww.kitovpharma.com Phone972-3933-3121FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick RatioN/A Sales & Book Value Annual Sales$1 million Price / Sales5.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book0.07Miscellaneous Outstanding Shares15,725,000Free FloatN/AMarket Cap$5.82 million OptionableNot Optionable Beta2.37 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Isaac Israel (Age 42)CEO & Director Comp: $564.48kMr. Gil Efron CPA (Age 54)Deputy CEO & CFO Comp: $356.91kMr. Avraham Shlomo Ben-Tzvi (Age 49)Group Chief Legal Officer, Gen. Counsel & Corp. Sec. Mr. Simcha Rock CPA (Age 70)M.B.A., CPA, MBA, Strategic Advisor & Director Dr. Bertrand C. Liang (Age 57)Chief Medical Officer Dr. Michael Schickler (Age 62)Head of Clinical Operations More ExecutivesKey CompetitorsOrgenesisNASDAQ:ORGSSol-Gel TechnologiesNASDAQ:SLGLAprea TherapeuticsNASDAQ:APREImmunoPrecise AntibodiesNASDAQ:IPASpruce BiosciencesNASDAQ:SPRBView All Competitors KTOV Stock Analysis - Frequently Asked Questions When did Purple Biotech's stock split? Purple Biotech's stock reverse split before market open on Saturday, August 22nd 2020. The 1-10 reverse split was announced on Friday, August 21st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 21st 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Purple Biotech IPO? Purple Biotech (KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar served as the underwriters for the IPO. What other stocks do shareholders of Purple Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Purple Biotech investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Southwestern Energy (SWN), VBI Vaccines (VBIV), Onconova Therapeutics (ONTX) and Advanced Micro Devices (AMD). This page (NASDAQ:KTOV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.